Meeting
2014 ASCO Annual Meeting
Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy.
Authors
Caicun Zhou
Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Caicun Zhou , Yunchao Huang , Changshan An , Donglin Wang , Jianxing He , Fuxiang Zhou , Gongyan Chen , Yali Li , Changping Wu , Gang Wu , Xia Song , Jianfei Gao , Wei Liu , Baolan Li , Jianhua Shi , Cheng Huang , Ping Yu , Jueping Feng , Yi Liu , Jielai Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01560195
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9614^)
DOI
10.1200/jco.2014.32.15_suppl.9614
Abstract #
9614^
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2015 ASCO Annual Meeting
An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.
First Author: Jianxing He
Poster
2014 ASCO Annual Meeting
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
First Author: Tony Mok
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu